The DOI matches its Crossref record; 117 of the 117 references it cites were found in a registry or an index.
MYC as a target for cancer treatment
Open accessAbstract
The MYC gene which consists of 3 paralogs, C-MYC, N-MYC and L-MYC, is one of the most frequently deregulated driver genes in human cancer. Because of its high prevalence of deregulation and its causal role in cancer formation, maintenance and progression, targeting MYC is theoretically an attractive strategy for treating cancer. As a potential anticancer target, MYC was traditionally regarded as undruggable due to the absence of a suitable pocket for high-affinity binding by low molecular weight inhibitors. In recent years however, several compounds that directly or indirectly inhibit MYC have been shown to have anticancer activity in preclinical tumor models. Amongst the most detailed investigated strategies for targeting MYC are inhibition of its binding to its obligate interaction partner MAX, prevention of MYC expression and blocking of genes exhibiting synthetic lethality with overexpression of MYC. One of the most extensively investigated MYC inhibitors is a peptide/mini-protein known as OmoMYC. OmoMYC, which acts by blocking the binding of all 3 forms of MYC to their target promoters, has been shown to exhibit anticancer activity in a diverse range of preclinical models, with minimal side effects. Based on its broad efficacy and limited toxicity, OmoMYC is currently being developed for evaluation in clinical trials. Although no compound directly targeting MYC has yet progressed to clinical testing, APTO-253, which partly acts by decreasing expression of MYC, is currently undergoing a phase I clinical trial in patients with relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dang, C. V. (2012) · Cell · doi:10.1016/j.cell.2012.03.003 · Cited by 3,390
BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
Delmore, J. E., Issa, G. C., Lemieux, M. E., Rahl, P. B., Shi, J., Jacobs, H. M., Kastritis, E., Gilpatrick, T., Paranal, R. M., Qi, J., et al. (2011) · Cell · doi:10.1016/j.cell.2011.08.017 · Cited by 2,813
Association of Multiple Copies of the N-myc Oncogene with Rapid Progression of Neuroblastomas
Seeger, R. C., Brodeur, G. M., Sather, H., Dalton, A., Siegel, S. E., Wong, K. Y., & Hammond, D. (1985) · New England Journal of Medicine · doi:10.1056/nejm198510313131802 · Cited by 2,010
RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia
Zuber, J., Shi, J., Wang, E., Rappaport, A. R., Herrmann, H., Sison, E. A., Magoon, D., Qi, J., Blatt, K., Wunderlich, M., et al. (2011) · Nature · doi:10.1038/nature10334 · Cited by 1,870
The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice
Adams, J. M., Harris, A. W., Pinkert, C. A., Corcoran, L. M., Alexander, W. S., Cory, S., Palmiter, R. D., & Brinster, R. L. (1985) · Nature · doi:10.1038/318533a0 · Cited by 1,779
Reflecting on 25 years with MYC
Meyer, N., & Penn, L. Z. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2231 · Cited by 1,575
Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia
Dawson, M. A., Prinjha, R. K., Dittmann, A., Giotopoulos, G., Bantscheff, M., Chan, W.-I., Robson, S. C., Chung, C.-W., Hopf, C., Savitski, M. M., et al. (2011) · Nature · doi:10.1038/nature10509 · Cited by 1,503
MYC regulates the antitumor immune response through CD47 and PD-L1
Casey, S. C., Tong, L., Li, Y., Do, R., Walz, S., Fitzgerald, K. N., Gouw, A. M., Baylot, V., Gütgemann, I., Eilers, M., et al. (2016) · Science · doi:10.1126/science.aac9935 · Cited by 1,403
Dang, C. V., O’Donnell, K. A., Zeller, K. I., Nguyen, T., Osthus, R. C., & Li, F. (2006) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2006.07.014 · Cited by 1,188
Targeting MYC dependence in cancer by inhibiting BET bromodomains
Mertz, J. A., Conery, A. R., Bryant, B. M., Sandy, P., Balasubramanian, S., Mele, D. A., Bergeron, L., & Sims, R. J. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1108190108 · Cited by 1,110
Genomic targets of the human c-Myc protein
Fernandez, P. C., Frank, S. R., Wang, L., Schroeder, M., Liu, S., Greene, J., Cocito, A., & Amati, B. (2003) · Genes & Development · doi:10.1101/gad.1067003 · Cited by 973
The Mechanisms behind the Therapeutic Activity of BET Bromodomain Inhibition
Shi, J., & Vakoc, C. R. (2014) · Molecular Cell · doi:10.1016/j.molcel.2014.05.016 · Cited by 878
Modelling Myc inhibition as a cancer therapy
Soucek, L., Whitfield, J., Martins, C. P., Finch, A. J., Murphy, D. J., Sodir, N. M., Karnezis, A. N., Swigart, L. B., Nasi, S., & Evan, G. I. (2008) · Nature · doi:10.1038/nature07260 · Cited by 817
Phosphorylation‐dependent degradation of c‐Myc is mediated by the F‐box protein Fbw7
Yada, M., Hatakeyama, S., Kamura, T., Nishiyama, M., Tsunematsu, R., Imaki, H., Ishida, N., Okumura, F., Nakayama, K., & Nakayama, K. I. (2004) · The EMBO Journal · doi:10.1038/sj.emboj.7600217 · Cited by 808
The novel ATM-related protein TRRAP is an essential cofactor for the c-Myc and E2F oncoproteins
McMahon, S. B., Van Buskirk, H. A., Dugan, K. A., Copeland, T. D., & Cole, M. D. (1998) · Cell · doi:10.1016/s0092-8674(00)81479-8 · Cited by 693
c-Myc binds to human ribosomal DNA and stimulates transcription of rRNA genes by RNA polymerase I
Grandori, C., Gomez-Roman, N., Felton-Edkins, Z. A., Ngouenet, C., Galloway, D. A., Eisenman, R. N., & White, R. J. (2005) · Nature Cell Biology · doi:10.1038/ncb1224 · Cited by 665
L-myc, a new myc-related gene amplified and expressed in human small cell lung cancer
Nau, M. M., Brooks, B. J., Battey, J., Sausville, E., Gazdar, A. F., Kirsch, I. R., McBride, O. W., Bertness, V., Hollis, G. F., & Minna, J. D. (1985) · Nature · doi:10.1038/318069a0 · Cited by 665
Non-transcriptional control of DNA replication by c-Myc
Dominguez-Sola, D., Ying, C. Y., Grandori, C., Ruggiero, L., Chen, B., Li, M., Galloway, D. A., Gu, W., Gautier, J., & Dalla-Favera, R. (2007) · Nature · doi:10.1038/nature05953 · Cited by 651
Sustained Loss of a Neoplastic Phenotype by Brief Inactivation of MYC
Jain, M., Arvanitis, C., Chu, K., Dewey, W., Leonhardt, E., Trinh, M., Sundberg, C. D., Bishop, J. M., & Felsher, D. W. (2002) · Science · doi:10.1126/science.1071489 · Cited by 644
CDK7 Inhibition Suppresses Super-Enhancer-Linked Oncogenic Transcription in MYCN-Driven Cancer
Chipumuro, E., Marco, E., Christensen, C. L., Kwiatkowski, N., Zhang, T., Hatheway, C. M., Abraham, B. J., Sharma, B., Yeung, C., Altabef, A., et al. (2014) · Cell · doi:10.1016/j.cell.2014.10.024 · Cited by 631
Myc Cooperates with Ras by Programming Inflammation and Immune Suppression
Kortlever, R. M., Sodir, N. M., Wilson, C. H., Burkhart, D. L., Pellegrinet, L., Brown Swigart, L., Littlewood, T. D., & Evan, G. I. (2017) · Cell · doi:10.1016/j.cell.2017.11.013 · Cited by 553
A global transcriptional regulatory role for c-Myc in Burkitt's lymphoma cells
Li, Z., Van Calcar, S., Qu, C., Cavenee, W. K., Zhang, M. Q., & Ren, B. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1332764100 · Cited by 524
Global mapping of c-Myc binding sites and target gene networks in human B cells
Zeller, K. I., Zhao, X., Lee, C. W. H., Chiu, K. P., Yao, F., Yustein, J. T., Ooi, H. S., Orlov, Y. L., Shahab, A., Yong, H. C., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0604129103 · Cited by 516
Activation and repression by oncogenic MYC shape tumour-specific gene expression profiles
Walz, S., Lorenzin, F., Morton, J., Wiese, K. E., von Eyss, B., Herold, S., Rycak, L., Dumay-Odelot, H., Karim, S., Bartkuhn, M., et al. (2014) · Nature · doi:10.1038/nature13473 · Cited by 502
Selective transcriptional regulation by Myc in cellular growth control and lymphomagenesis
Sabò, A., Kress, T. R., Pelizzola, M., de Pretis, S., Gorski, M. M., Tesi, A., Morelli, M. J., Bora, P., Doni, M., Verrecchia, A., et al. (2014) · Nature · doi:10.1038/nature13537 · Cited by 489
CDK7-Dependent Transcriptional Addiction in Triple-Negative Breast Cancer
Wang, Y., Zhang, T., Kwiatkowski, N., Abraham, B. J., Lee, T. I., Xie, S., Yuzugullu, H., Von, T., Li, H., Lin, Z., et al. (2015) · Cell · doi:10.1016/j.cell.2015.08.063 · Cited by 465
Small-Molecule MYC Inhibitors Suppress Tumor Growth and Enhance Immunotherapy
Han, H., Jain, A. D., Truica, M. I., Izquierdo-Ferrer, J., Anker, J. F., Lysy, B., Sagar, V., Luan, Y., Chalmers, Z. R., Unno, K., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.10.001 · Cited by 465
Distinct Thresholds Govern Myc's Biological Output In Vivo
Murphy, D. J., Junttila, M. R., Pouyet, L., Karnezis, A., Shchors, K., Bui, D. A., Brown-Swigart, L., Johnson, L., & Evan, G. I. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.10.018 · Cited by 456
MYC Deregulation in Primary Human Cancers
Kalkat, M., De Melo, J., Hickman, K., Lourenco, C., Redel, C., Resetca, D., Tamachi, A., Tu, W., & Penn, L. (2017) · Genes · doi:10.3390/genes8060151 · Cited by 443
Targeting Transcriptional Addictions in Small Cell Lung Cancer with a Covalent CDK7 Inhibitor
Christensen, C. L., Kwiatkowski, N., Abraham, B. J., Carretero, J., Al-Shahrour, F., Zhang, T., Chipumuro, E., Herter-Sprie, G. S., Akbay, E. A., Altabef, A., et al. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.10.019 · Cited by 439
Direct activation of RNA polymerase III transcription by c-Myc
Gomez-Roman, N., Grandori, C., Eisenman, R. N., & White, R. J. (2003) · Nature · doi:10.1038/nature01327 · Cited by 433
Pan-cancer Alterations of the MYC Oncogene and Its Proximal Network across the Cancer Genome Atlas
Schaub, F. X., Dhankani, V., Berger, A. C., Trivedi, M., Richardson, A. B., Shaw, R., Zhao, W., Zhang, X., Ventura, A., Liu, Y., et al. (2018) · Cell Systems · doi:10.1016/j.cels.2018.03.003 · Cited by 431
Low molecular weight inhibitors of Myc–Max interaction and function
Yin, X., Giap, C., Lazo, J. S., & Prochownik, E. V. (2003) · Oncogene · doi:10.1038/sj.onc.1206641 · Cited by 428
An Overview of MYC and Its Interactome
Conacci-Sorrell, M., McFerrin, L., & Eisenman, R. N. (2014) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a014357 · Cited by 408
MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition
Horiuchi, D., Kusdra, L., Huskey, N. E., Chandriani, S., Lenburg, M. E., Gonzalez-Angulo, A. M., Creasman, K. J., Bazarov, A. V., Smyth, J. W., Davis, S. E., et al. (2012) · Journal of Experimental Medicine · doi:10.1084/jem.20111512 · Cited by 378
Binding of myc proteins to canonical and noncanonical DNA sequences.
Blackwell, T. K., Huang, J., Ma, A., Kretzner, L., Alt, F. W., Eisenman, R. N., & Weintraub, H. (1993) · Molecular and Cellular Biology · doi:10.1128/mcb.13.9.5216 · Cited by 376
BET inhibitors: a novel epigenetic approach
Doroshow, D. B., Eder, J. P., & LoRusso, P. M. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx157 · Cited by 367
An alternative pathway for gene regulation by Myc
Peukert, K. (1997) · The EMBO Journal · doi:10.1093/emboj/16.18.5672 · Cited by 364
Lockwood, W. W., Zejnullahu, K., Bradner, J. E., & Varmus, H. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1216363109 · Cited by 327
Inhibition of CDK1 as a potential therapy for tumors over-expressing MYC
Goga, A., Yang, D., Tward, A. D., Morgan, D. O., & Bishop, J. M. (2007) · Nature Medicine · doi:10.1038/nm1606 · Cited by 326
Inhibition of Myc family proteins eradicates KRas-driven lung cancer in mice
Soucek, L., Whitfield, J. R., Sodir, N. M., Massó-Vallés, D., Serrano, E., Karnezis, A. N., Swigart, L. B., & Evan, G. I. (2013) · Genes & Development · doi:10.1101/gad.205542.112 · Cited by 301
Strategies to Inhibit Myc and Their Clinical Applicability
Whitfield, J. R., Beaulieu, M.-E., & Soucek, L. (2017) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2017.00010 · Cited by 294
The MYC transcription factor network: balancing metabolism, proliferation and oncogenesis
Carroll, P. A., Freie, B. W., Mathsyaraja, H., & Eisenman, R. N. (2018) · Frontiers of Medicine · doi:10.1007/s11684-018-0650-z · Cited by 289
Recent Progress of Targeted G-Quadruplex-Preferred Ligands Toward Cancer Therapy
Asamitsu, S., Obata, S., Yu, Z., Bando, T., & Sugiyama, H. (2019) · Molecules · doi:10.3390/molecules24030429 · Cited by 275
Hayes, T. K., Neel, N. F., Hu, C., Gautam, P., Chenard, M., Long, B., Aziz, M., Kassner, M., Bryant, K. L., Pierobon, M., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2015.11.011 · Cited by 264
Translation control of the immune checkpoint in cancer and its therapeutic targeting
Xu, Y., Poggio, M., Jin, H. Y., Shi, Z., Forester, C. M., Wang, Y., Stumpf, C. R., Xue, L., Devericks, E., So, L., et al. (2019) · Nature Medicine · doi:10.1038/s41591-018-0321-2 · Cited by 261
The MYC oncogene is a global regulator of the immune response
Casey, S. C., Baylot, V., & Felsher, D. W. (2018) · Blood · doi:10.1182/blood-2017-11-742577 · Cited by 259
Liu, P., Cheng, H., Santiago, S., Raeder, M., Zhang, F., Isabella, A., Yang, J., Semaan, D. J., Chen, C., Fox, E. A., et al. (2011) · Nature Medicine · doi:10.1038/nm.2402 · Cited by 257
BRD4 Sustains Melanoma Proliferation and Represents a New Target for Epigenetic Therapy
Segura, M. F., Fontanals-Cirera, B., Gaziel-Sovran, A., Guijarro, M. V., Hanniford, D., Zhang, G., González-Gomez, P., Morante, M., Jubierre, L., Zhang, W., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-0122-t · Cited by 239
MYC inhibition induces metabolic changes leading to accumulation of lipid droplets in tumor cells
Zirath, H., Frenzel, A., Oliynyk, G., Segerström, L., Westermark, U. K., Larsson, K., Munksgaard Persson, M., Hultenby, K., Lehtiö, J., Einvik, C., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1222404110 · Cited by 235
Inhibition of BET bromodomains as a therapeutic strategy for cancer drug discovery
Fu, L.-L., Tian, M., Li, X., Li, J.-J., Huang, J., Ouyang, L., Zhang, Y., & Liu, B. (2015) · Oncotarget · doi:10.18632/oncotarget.3551 · Cited by 221
Design and properties of a Myc derivative that efficiently homodimerizes
Soucek, L., Helmer-Citterich, M., Sacco, A., Jucker, R., Cesareni, G., & Nasi, S. (1998) · Oncogene · doi:10.1038/sj.onc.1202199 · Cited by 221
Lüscher, B., & Larsson, L.-G. (1999) · Oncogene · doi:10.1038/sj.onc.1202750 · Cited by 212
Intrinsic cell-penetrating activity propels Omomyc from proof of concept to viable anti-MYC therapy
Beaulieu, M.-E., Jauset, T., Massó-Vallés, D., Martínez-Martín, S., Rahl, P., Maltais, L., Zacarias-Fluck, M. F., Casacuberta-Serra, S., Serrano del Pozo, E., Fiore, C., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aar5012 · Cited by 209
Kalkat, M., Resetca, D., Lourenco, C., Chan, P.-K., Wei, Y., Shiah, Y.-J., Vitkin, N., Tong, Y., Sunnerhagen, M., Done, S. J., et al. (2018) · Molecular Cell · doi:10.1016/j.molcel.2018.09.031 · Cited by 201
Improved low molecular weight Myc-Max inhibitors
Wang, H., Hammoudeh, D. I., Follis, A. V., Reese, B. E., Lazo, J. S., Metallo, S. J., & Prochownik, E. V. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0005 · Cited by 190
Follis, A. V., Hammoudeh, D. I., Wang, H., Prochownik, E. V., & Metallo, S. J. (2008) · Chemistry & Biology · doi:10.1016/j.chembiol.2008.09.011 · Cited by 183
MYC Instructs and Maintains Pancreatic Adenocarcinoma Phenotype
Sodir, N. M., Kortlever, R. M., Barthet, V. J. A., Campos, T., Pellegrinet, L., Kupczak, S., Anastasiou, P., Swigart, L. B., Soucek, L., Arends, M. J., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0435 · Cited by 182
Baudino, T. A., & Cleveland, J. L. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.3.691-702.2001 · Cited by 179
Yang, D., Liu, H., Goga, A., Kim, S., Yuneva, M., & Bishop, J. M. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1008366107 · Cited by 177
Horiuchi, D., Camarda, R., Zhou, A. Y., Yau, C., Momcilovic, O., Balakrishnan, S., Corella, A. N., Eyob, H., Kessenbrock, K., Lawson, D. A., et al. (2016) · Nature Medicine · doi:10.1038/nm.4213 · Cited by 170
Small-molecule inhibitors of the Myc oncoprotein
Fletcher, S., & Prochownik, E. V. (2014) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2014.03.005 · Cited by 161
Oncogenic regulation of tumor metabolic reprogramming
Tarrado-Castellarnau, M., de Atauri, P., & Cascante, M. (2016) · Oncotarget · doi:10.18632/oncotarget.10911 · Cited by 161
Different promoter affinities account for specificity in MYC-dependent gene regulation
Lorenzin, F., Benary, U., Baluapuri, A., Walz, S., Jung, L. A., von Eyss, B., Kisker, C., Wolf, J., Eilers, M., & Wolf, E. (2016) · eLife · doi:10.7554/elife.15161 · Cited by 161
Omomyc, a potential Myc dominant negative, enhances Myc-induced apoptosis.
Soucek, L., Jucker, R., Panacchia, L., Ricordy, R., Tatò, F., & Nasi, S. (2002) · PubMed · Cited by 160
Carey, J. P. W., Karakaş, C., Bui, T. N., Chen, X., Vijayaraghavan, S., Zhao, Y., Wang, J., Mikule, K. W., Litton, J. K., Hunt, K. K., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-1494 · Cited by 151
Inhibitor of MYC identified in a Kröhnke pyridine library
Hart, J. R., Garner, A. L., Yu, J., Ito, Y., Sun, M., Ueno, L. A., Rhee, J., Baksh, M. M., Stefan, E., Hartl, M., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1319488111 · Cited by 150
Blocking Myc to Treat Cancer: Reflecting on Two Decades of Omomyc
Massó-Vallés, D., & Soucek, L. (2020) · Cells · doi:10.3390/cells9040883 · Cited by 147
Savino, M., Annibali, D., Carucci, N., Favuzzi, E., Cole, M. D., Evan, G. I., Soucek, L., & Nasi, S. (2011) · PLoS ONE · doi:10.1371/journal.pone.0022284 · Cited by 136
Castell, A., Yan, Q., Fawkner, K., Hydbring, P., Zhang, F., Verschut, V., Franco, M., Zakaria, S. M., Bazzar, W., Goodwin, J., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-28107-4 · Cited by 133
Stabilization of the Max Homodimer with a Small Molecule Attenuates Myc-Driven Transcription
Struntz, N. B., Chen, A., Deutzmann, A., Wilson, R. M., Stefan, E., Evans, H. L., Ramirez, M. A., Liang, T., Caballero, F., Wildschut, M. H. E., et al. (2019) · Cell Chemical Biology · doi:10.1016/j.chembiol.2019.02.009 · Cited by 130
Wiegering, A., Uthe, F. W., Jamieson, T. J., Ruoss, Y., Hüttenrauch, M., Küspert, M., Pfann, C., Nixon, C., Herold, S., Walz, S., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-1040 · Cited by 123
Guo, J., Parise, R. A., Joseph, E., Egorin, M. J., Lazo, J. S., Prochownik, E. V., & Eiseman, J. L. (2008) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-008-0774-y · Cited by 123
Shostak, A., Ruppert, B., Ha, N., Bruns, P., Toprak, U. H., ICGC MMML-Seq Project, Lawerenz, C., Lichter, P., Radlwimmer, B., Eils, J., et al. (2016) · Nature Communications · doi:10.1038/ncomms11807 · Cited by 121
Tu, W. B., Shiah, Y.-J., Lourenco, C., Mullen, P. J., Dingar, D. D., Redel, C., Tamachi, A., Ba-Alawi, W., Aman, A. M., Al‐awar, R., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.09.001 · Cited by 119
Thomas, L. R., Adams, C. M., Wang, J., Weissmiller, A. M., Creighton, J. H., Lorey, S. L., Liu, Q., Fesik, S. W., Eischen, C. M., & Tansey, W. P. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1910391116 · Cited by 118
Beaulieu, M.-È., Castillo, F., & Soucek, L. (2020) · Cells · doi:10.3390/cells9041038 · Cited by 116
Novel c‐MYC target genes mediate differential effects on cell proliferation and migration
Cappellen, D., Schlange, T., Bauer, M., Maurer, F., & Hynes, N. E. (2006) · EMBO Reports · doi:10.1038/sj.embor.7400849 · Cited by 114
Recent insight into the role of FBXW7 as a tumor suppressor
Yumimoto, K., & Nakayama, K. I. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.02.017 · Cited by 111
Cowling, V. H., Chandriani, S. J., Whitfield, M. L., & Cole, M. D. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.01959-05 · Cited by 102
Jung, L. A., Gebhardt, A., Koelmel, W., Ade, C. P., Walz, S., Kuper, J., von Eyss, B., Letschert, S., Redel, C., d'Artista, L., et al. (2017) · Oncogene · doi:10.1038/onc.2016.354 · Cited by 101
A conserved element in Myc that negatively regulates its proapoptotic activity
Herbst, A., Hemann, M. T., Tworkowski, K. A., Salghetti, S. E., Lowe, S. W., & Tansey, W. P. (2005) · EMBO Reports · doi:10.1038/sj.embor.7400333 · Cited by 100
A β-catenin/TCF-coordinated chromatin loop at MYC integrates 5′ and 3′ Wnt responsive enhancers
Yochum, G. S., Sherrick, C. M., MacPartlin, M., & Goodman, R. H. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0912294107 · Cited by 98
Targeting of the MYCN Protein with Small Molecule c-MYC Inhibitors
Müller, I., Larsson, K., Frenzel, A., Oliynyk, G., Zirath, H., Prochownik, E. V., Westwood, N. J., & Arsenian‐Henriksson, M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0097285 · Cited by 97
Omomyc Reveals New Mechanisms To Inhibit the MYC Oncogene
Demma, M. J., Mapelli, C., Sun, A., Bodea, S., Ruprecht, B., Javaid, S., Wiswell, D., Muise, E., Chen, S., Zelina, J., et al. (2019) · Molecular and Cellular Biology · doi:10.1128/mcb.00248-19 · Cited by 92
Santoro, A., Vlachou, T., Luzi, L., Melloni, G. E. M., Mazzarella, L., D’Elia, E., Xieraili, A., Pasi, C. E., Reavie, L. B., Bonetti, P., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2018.12.071 · Cited by 89
Wang, E., Sorolla, A., Cunningham, P. T., Bogdawa, H. M., Beck, S. J., Golden, E., Dewhurst, R. E., Florez, L., Cruickshank, M. N., Hoffmann, K., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0421-y · Cited by 86
Discovery of Novel Myc−Max Heterodimer Disruptors with a Three-Dimensional Pharmacophore Model
Mustata, G. I., Follis, A. V., Hammoudeh, D. I., Metallo, S. J., Wang, H., Prochownik, E. V., Lazo, J. S., & Bahar, İ. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm801278g · Cited by 85
Local, A., Zhang, H., Benbatoul, K. D., Folger, P., Sheng, X., Tsai, C., Howell, S. B., & Rice, W. G. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-1209 · Cited by 85
Human MYC G-quadruplex: From discovery to a cancer therapeutic target
Wang, W., Hu, S., Gu, Y., Yan, Y., Stovall, D. B., Li, D., & Sui, G. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188410 · Cited by 81
A Time for MYC: Metabolism and TherapyPreprint
Dang, C. V. (2016) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2016.81.031153 · Cited by 78
Chacón Simon, S., Wang, F., Thomas, L. R., Phan, J., Zhao, B., Olejniczak, E. T., Macdonald, J. D., Shaw, J. G., Schlund, C., Payne, W., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00224 · Cited by 76
c-MYC Drives Breast Cancer Metastasis to the Brain, but Promotes Synthetic Lethality with TRAIL
Lee, H. Y., Cha, J., Kim, S., Park, J., Song, K. H., Kim, P., & Kim, M. (2018) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-18-0630 · Cited by 70
Clinical and Biologic Significance of MYC Genetic Mutations in De Novo Diffuse Large B-cell Lymphoma
Xu-Monette, Z. Y., Deng, Q., Manyam, G. C., Tzankov, A., Li, L., Xia, Y., Wang, X., Zou, D., Visco, C., Dybkær, K., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2296 · Cited by 66
Targeting MYC Proteins for Tumor Therapy
Wolf, E., & Eilers, M. (2019) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030518-055826 · Cited by 65
Mikulášová, A., Ashby, C., Tytarenko, R. G., Qu, P., Rosenthal, A., Dent, J. A., Ryan, K. R., Bauer, M., Wardell, C. P., Hoering, A., et al. (2019) · Haematologica · doi:10.3324/haematol.2019.217927 · Cited by 63
Stabilizers of the Max Homodimer Identified in Virtual Ligand Screening Inhibit Myc Function
Jiang, H., Bower, K. E., Beuscher, A. E., Zhou, B., Bobkov, A. A., Olson, A. J., & Vogt, P. K. (2009) · Molecular Pharmacology · doi:10.1124/mol.109.054858 · Cited by 62
Integrative analysis of RNA polymerase II and transcriptional dynamics upon MYC activationPreprint
de Pretis, S., Kress, T. R., Morelli, M. J., Sabò, A., Locarno, C. V., Verrecchia, A., Doni, M., Campaner, S., Amati, B. B., & Pelizzola, M. (2017) · Genome Research · doi:10.1101/gr.226035.117 · Cited by 59
Thomas, L. R., Foshage, A. M., Weissmiller, A. M., Popay, T. M., Grieb, B. C., Qualls, S. J., Ng, V. H., Carboneau, L., Lorey, S. L., Eischen, C. M., et al. (2015) · Oncogene · doi:10.1038/onc.2015.416 · Cited by 51
Pathogenesis and therapeutic targeting of aberrant MYC expression in haematological cancers
Schick, M., Habringer, S., Nilsson, J. A., & Keller, U. B. (2017) · British Journal of Haematology · doi:10.1111/bjh.14917 · Cited by 47
Cercek, A., Wheler, J. J., Murray, P. E., Zhou, S., & Saltz, L. B. (2015) · Investigational New Drugs · doi:10.1007/s10637-015-0273-z · Cited by 45
c-MYC regulates mRNA translation efficiency and start-site selection in lymphoma
Singh, K., Lin, J., Zhong, Y., Burčul, A., Mohan, P., Jiang, M., Sun, L. L., Yong‐Gonzalez, V., Viale, A. J., Cross, J. R., et al. (2019) · The Journal of Experimental Medicine · doi:10.1084/jem.20181726 · Cited by 44
Inhibiting MYC binding to the E-box DNA motif by ME47 decreases tumour xenograft growth
Lustig, L. C., Dingar, D. D., Tu, W. B., Lourenco, C., Kalkat, M., Inamoto, I., Ponzielli, R., Chan, W. C. W., Shin, J. A., & Penn, L. Z. (2017) · Oncogene · doi:10.1038/onc.2017.275 · Cited by 41
MYCN acts as a direct co-regulator of p53 in MYCN amplified neuroblastoma
Agarwal, S., Milazzo, G., Rajapakshe, K., Bernardi, R. J., Chen, Z., Barbieri, E., Köster, J., Perini, G., Coarfa, C., & Shohet, J. M. (2018) · Oncotarget · doi:10.18632/oncotarget.24859 · Cited by 40
Antitumor efficacy of PARP inhibitors in homologous recombination deficient carcinomas
Yi, T., Feng, Y., Sundaram, R., Tie, Y., Zheng, H., Qian, Y., You, D., Yi, T., Wang, P., & Zhao, X. (2019) · International Journal of Cancer · doi:10.1002/ijc.32143 · Cited by 38
Targeting MYC Translation in Colorectal Cancer
Castell, A., & Larsson, L. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0660 · Cited by 37
Direct Targeting of MYCN Gene Amplification by Site-Specific DNA Alkylation in Neuroblastoma
Yoda, H., Inoue, T., Shinozaki, Y., Lin, J. C., Watanabe, T., Koshikawa, N., Takatori, A., & Nagase, H. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-1198 · Cited by 36
Huesca, M., Lock, L. S., Khine, A. A., Viau, S., Peralta, R., Cukier, I. H., Jin, H., Al‐Qawasmeh, R. A., Lee, Y., Wright, J., et al. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-1104 · Cited by 34
The Myc and Ras Partnership in Cancer: Indistinguishable Alliance or Contextual Relationship?
Mahauad‐Fernandez, W. D., & Felsher, D. W. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-0787 · Cited by 32
Myc, Aurora Kinase A, and mutant p53R172H co-operate in a mouse model of metastatic skin carcinoma
Torchia, E. C., Caulín, C., Acín, S., Terzian, T., Kubick, B. J., Box, N. F., & Roop, D. R. (2011) · Oncogene · doi:10.1038/onc.2011.441 · Cited by 29
Cyclin-dependent kinase inhibitors for the treatment of chronic lymphocytic leukemia
Blachly, J. S., Byrd, J. C., & Grever, M. R. (2016) · Seminars in Oncology · doi:10.1053/j.seminoncol.2016.02.003 · Cited by 28
AlSultan, D., Kavanagh, E. L., O’Grady, S., Eustace, A. J., Castell, A., Larsson, L., Crown, J. P., Madden, S. F., & Duffy, M. J. (2020) · Investigational New Drugs · doi:10.1007/s10637-020-01018-w · Cited by 28
Self-citationAPTO-253 Is a New Addition to the Repertoire of Drugs that Can Exploit DNA BRCA1/2 Deficiency
Tsai, C., Sun, S., Zhang, H., Local, A., Su, Y., Gross, L. A., Rice, W. G., & Howell, S. B. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0834 · Cited by 22
Zhang, Q., West-Osterfield, K., Spears, E., Li, Z., Panaccione, A., & Hann, S. (2017) · Genes · doi:10.3390/genes8050134 · Cited by 17
Long path to MYC inhibition approaches clinical trials
Villanueva, M. T. (2019) · Nature reviews. Cancer · doi:10.1038/s41568-019-0141-9 · Cited by 16
The new role for an old guy: MYC as an immunoplayer
Marinković, D., & Marinković, T. (2020) · Journal of Cellular Physiology · doi:10.1002/jcp.30123 · Cited by 12
Tracing MYC Expression for Small Molecule Discovery
Steinberger, J., Robert, F., Hallé, M., Williams, D. E., Cencic, R., Sawhney, N., Pelletier, D., Williams, P. G., Igarashi, Y., Porco, J. A. J., et al. (2019) · Cell chemical biology · doi:10.1016/j.chembiol.2019.02.007 · Cited by 11
Cited by
Li, Z., Lai, X., Fu, S., Ren, L., Cai, H., Zhang, H., Gu, Z., Ma, X., & Luo, K. (2022) · Advanced Science · doi:10.1002/advs.202201734 · Cited by 680
Therapeutic targeting of “undruggable” MYC
Llombart, V., & Mansour, M. R. (2022) · eBioMedicine · doi:10.1016/j.ebiom.2021.103756 · Cited by 472
PROTACs: great opportunities for academia and industry (an update from 2020 to 2021)
He, M., Cao, C., Ni, Z., Liu, Y., Song, P., Hao, S., He, Y., Sun, X., & Rao, Y. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00999-9 · Cited by 283
Small molecules targeting protein–protein interactions for cancer therapy
Wu, D., Li, Y., Zheng, L., Xiao, H., Ouyang, L., Wang, G., & Sun, Q. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.05.035 · Cited by 71
Jiang, B., Ding, T., Guo, C., Bai, X., Cao, D., Wu, X., Sha, W., Jiang, M., Wu, L., & Gao, Y. (2022) · Advanced Science · doi:10.1002/advs.202201300 · Cited by 54
Metadata
- Authors
- Duffy, M. J., O'Grady, S., Tang, M., & Crown, J.
- Venue
- Cancer Treatment Reviews
- Publisher
- Elsevier BV
- Published
- 2021-03
- Volume
- 94
- Pages
- 102154
- ISSN
- 0305-7372 (ISSN-L)
- OpenAlex
- W3125923658
- Cited by
- 514
- References
- 117
- FWCI
- 27.07
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.